Abstract

While innovations in cancer therapy have significantly enhanced the overall survival rates of cancer patients over the past five decades, there remain unmet medical needs for diverse patient populations. Beyond the conventional approaches of small molecule inhibitors and monoclonal antibodies, BeiGene has expanded its portfolio to encompass a variety of modalities. These include, but are not limited to, multispecific antibodies, antibody-drug conjugates (ADCs), and Chimeric Degradation Activation Compounds (CDACs). By integrating our disease understanding, which is grounded in translational research, with our differentiated platforms, we aim to more effectively design first-in-class (FIC) and best-in-class (BIC) innovative medicines.